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ABSTRACT 
  Carcinoembryonic Antigen (CEA) is an approved cancer biomarker by the Food and Drug 
Administration (FDA) for the early detection, diagnosis, and for the use in the regular screening 
of patients at high risk for the development of cancer. Traditional methods to determine the 
concentrations of CEA are based on utilizing antibodies. In this project, a graphene oxide (GO)–
assisted systematic evolution of ligands through exponential enrichment (SELEX) was used to 
identify DNA aptamers specific for CEA. The dissociation constants of the identified aptamers 
were determined with surface plasmon resonance (SPR). Comparison of the dissociation constants 
of aptamers isolated from the GO-based SELEX and affinity SELEX found the dissociation 
constant of the aptamers isolated from GO-assisted SELEX was three times lower than aptamers 
isolated from the affinity SELEX. The analytical applications of the identified aptamers were 
studied by developing a colorimetric test for the determination of CEA with un-modified gold 
nanoparticles. 
  
  
 
 
 
 
 
 
 
 
  iv 
ACKNOWLEDGEMENTS 
 
This work would not have been possible without the help and support of Dr. Guodong Liu 
and his group; Sunitha Takalkar, Kwaku Baryeh and Xiaoguang Zhang who taught me much in 
the laboratory practices. I would also like to thank the visiting scholars who also gave some 
perspective to the work accomplished; Qiaobin Li and Yan Huang. I would also like to thank the 
Dr. Stuart Harring for allowing the use of some of his laboratory instruments and Dr. Estelle 
Leclerc for teaching me how to run surface plasmon resonance experiments and for the use of the 
two channel Reichert 2 SPR for without her help the comparison of the two SELEX methods would 
not have been possible. Finally, I would like to thank the National Institute of Health’s Centers for 
Biomedical Research Excellence for which provided the funding for this research and it therefor 
would not be possible without this support.  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  v 
TABLE OF CONTENTS 
 
ABSTRACT ................................................................................................................................... iii 
ACKNOWLEDGMENTS  ............................................................................................................ iv 
LIST OF TABLES  ....................................................................................................................... vii 
LIST OF FIGURES  .................................................................................................................... viii 
LIST OF SCHEMES....................................................................................................................... x 
LIST OF ABBREVIATIONS ........................................................................................................ xi 
LIST OF SYMBOLS ................................................................................................................... xiii 
CHAPTER 1. INTRODUCTION ................................................................................................... 1 
1.1. Background of Carcinoembryonic Antigen ............................................................ 1 
1.2. Carcinoembryonic Antigen as a Biomarker  ........................................................... 2 
1.3. Introduction to Biosensors  ..................................................................................... 3 
1.4. Detection Methods of Carcinoembryonic Antigen  ................................................ 4 
1.5. Potential Improvements toward Reported Detection Methods ............................... 5 
1.6. Aptamers Implemented in Therapeutics and Diagnostics Purposes ....................... 6 
1.7. Aptamers Identified Toward Carcinoembryonic Antigen ...................................... 8 
1.8. Carcinoembryonic Antigen Aptamers Implicated in Analytical Techniques ....... 13 
1.9. Aims and Objectives of the Study ........................................................................ 14 
1.10. Significance of the Study ...................................................................................... 15 
1.11. Limitations of  the Study....................................................................................... 15 
CHAPTER 2. DEVELOPMENT OF CARCINOEMBRYONIC ANTIGEN APTAMERS 
UTILIZING GRAPHENE OXIDE ASSISTED SELEX .............................................................. 16  
2.1.  Literature Review of SELEX .................................................................................... 16 
2.2.  Materials and Methods .............................................................................................. 19 
2.2.1. Materials and Instrumentation for Graphene Oxide Assisted SELEX 
Experiment ............................................................................................................ 19 
  vi 
2.2.2 Graphene Oxide Assisted SELEX ............................................................... 20 
2.3. Results. ....................................................................................................................... 22 
2.4. Discussion .................................................................................................................. 24 
2. 5. Conclusion ................................................................................................................ 25 
CHAPTER 3. DETEMINATION OF DISSOCIATION CONSTANTS WITH SURFACE 
PLASMON RESONANCE .......................................................................................................... 26 
3.1. Literature Review of Methods for the Determination of Dissociation Constant ....... 26 
3.2. Materials and Methods ............................................................................................... 30 
3.2.1. Materials  .................................................................................................... 30 
3.2.2. Method of Conjugation ............................................................................... 31 
3.2.3. Dissociation Constant Titration and Determination ................................... 31 
3.3. Results. ....................................................................................................................... 33 
3.4. Discussion .................................................................................................................. 37 
3.5. Conclusion ................................................................................................................. 40 
CHAPTER 4. UTILIZATION OF UNMODIFIED GOLD NANOPARTICLES FOR 
THE COLORIMETRIC DETECTION OF CARCINOEMBRYONIC ANTIGEN .................... 41 
4.1. Literature Review of Gold Nanoparticles .................................................................. 41 
4.2. Materials and Methods ............................................................................................... 45 
4.2.1. Materials ..................................................................................................... 45 
4.2.2. Preparation of Gold Nanoparticles .............................................................. 45 
4.2.3 Detection of Carcinoembryonic Antigen ..................................................... 46 
4.3 Results. ........................................................................................................................ 47 
4.4 Discussion ................................................................................................................... 54 
4.5 Conclusion .................................................................................................................. 57 
CHAPTER 5. CONCLUSION...................................................................................................... 58 
REFERENCES ............................................................................................................................. 60 
  vii 
LIST OF TABLES 
Table                Page   
1. FDA Approved Aptamers for Proteins in Cancer …………………………………....................8 
2. Reported CEA Aptamers …………………………………………………………....………...12 
3. Aptamers Identified with GO-SELEX ……………………………………………................. 24 
4.  SPR Determined Dissociation Constant for Aptamer One ………………………………….. 34 
5. SPR Determined Dissociation Constant for Reported Aptamer ……………………………... 36 
6. Reproducibility of CEA Detection …………………………………………………………... 52 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  viii 
LIST OF FIGURES 
Figure                                      Page 
1. Affinity SELEX Method …………………………………………………………………… 10  
2. Negative Affinity SELEX Method...…………………….…………………………………. 11 
3. Colorimetric Method for the Detection of CEA Utilizing Specific Aptamer ....…………… 14 
4. Graphene Oxide Assisted SELEX ……………………………….………………………….18 
5. Percent of DNA Recovered from all Selection Rounds .…………………………………….23 
6. Percent of DNA Recovered for all Positive Rounds ……………………………………….. 23 
7. Proof of Conjugation of Aptamer onto the Gold Surface ………………………..………… 33 
8. Aptamer One Curve Fitting in Scrubber Application of Raw Data for the Calculation of 
Dissociation Constant ……………………………………………………………………… 34 
 
9. Curve fitting of the SPR Data to Calculate the Dissociation Constant for Aptamer One ..... 35 
 
10. Reported Aptamer Curve Fitting in Scrubber Application of Raw Data for the Calculation   
of Dissociation Constant …………………………….………………………………………36 
 
11. Curve Fitting of the SPR Data to Calculate the Dissociation Constant for Reported 
Aptamer……………………………………………………………………………………... 37 
 
12.  Aptamer Thiolated onto the Gold Nanoparticle Surface ……………………..…................ 43 
13. Aptamer Covalently Conjugated onto a Gold Nanoparticle Surface ……..………............... 44  
 
14. Unmodified Gold Nanoparticle Detection Method…………………………………………. 45 
15. Optimization of Buffer Types ……………………………………………………………….48 
16. Optimization of Starting Gold Nanoparticle Concentration ……………………………….  48 
17. Starting Aptamer Concentration Optimization …………………………………………….. 49 
18. Sodium Chloride Concentration Optimization …………………………………………….. 49 
19. DNA Absorption Time Optimization ……………………………………………………… 50 
20. Protein to DNA Binding Time Optimization ………………………………………………. 50 
  ix 
21. Reproducibility for Colorimetric Test ………………………………………....................... 51 
22. Selectivity for CEA Colorimetric Test.…………………………………………………….. 52 
23. Depiction of Color change in Colorimetric Test …………………………………………….53 
24. Calibration Curve for Aptamer One in Gold Colorimetric Test …………………………… 53 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  x 
LIST OF SCHEMES 
Scheme               Page 
1. Graphene Oxide Assisted SELEX showing Positive and Negative Selection 
Rounds……………………………………………………………………………………….21 
 
2. Representation of Surface Plasmon Resonance Experiment ……………………................. 32  
 
3. Representation of the Colorimetric Detection of CEA with Unmodified Gold     
Nanoparticles and CEA Aptamer One …………….……………………………………….. 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  xi 
LIST OF ABBREVIATIONS 
 
CEA …………………………………………………………............... Carcinoembryonic antigen  
SELEX ……………………….. Systematic evolution of ligands through exponential enrichment  
GO ……………………………………………………………………………….. Graphene oxide  
FDA………………………………………………………………. Food and Drug Administration 
CA 125 ………………………………………………………………............... cancer antigen 125  
ELISA ……………………………………………………... enzyme-linked immunosorbent assay  
RNA …………………………………………………………………………….. Ribonucleic acid  
DNA ………………………………………………………………………. Deoxyribonucleic acid  
ssDNA ………………………………………..................... Single stranded deoxyribonucleic acid  
PEG ………………………………………………………………………….. Polyethylene glycol  
AMD ……................................................................................... age-related macular degeneration 
IgE ………………………………………………………………………………. immunoglobin E  
SLE …………………………………………………............... Systematic Lupus Erythaematosus  
PDGF-r …………………………………………............... platelet derived growth factor receptor  
CTLA -4 …………………………………............... cytotoxic T-lymphocyte-associated protein 4 
PSMA ……………………………………………………….. Prostate specific membrane antigen   
POC ………………………………………………………………………………… Point of Care 
Con-A ……………………………………………………………………………….. concanavalin  
AuNPs ………………………………………………………………………… Gold nanoparticles  
Tris HCl ……. …………………………………………………………….. Trizma hydrochloride  
PCR …………………………………………………………………… polymerase chain reaction 
TCEP ……………………………………………………............... tris(2-carboxyethyl)phosphine  
  xii 
CE ……………………………………………………………………… Capillary electrophoresis  
SPR …………………………………………………………............... surface plasmon resonance  
NexGen Sequencing …………………………………………………. next generation sequencing  
ITC ………………………………………………………………............... isothermal calorimetry  
EMSA………………………………………………............... electrophoretic mobility shift assay  
HEPES……………………………............... 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
TWEEN …………………………………………………. Polyoxyethylene Sorbitan Monolaurate 
BSA ……………………………………………………………………... Bovine Serum Albumin 
HAuCl4……………………………………………………............... Gold (III) chloride trihydrate  
PBS ………………………………………………………………….. phosphate bufferered saline 
PBS(T)……………………………………………....………phosphate buffered saline with tween  
SSC………………………………………………………………………….. Saline sodium citrate 
RSD…………………………………………………………………… relative standard deviation 
CA 19-9………………………………………………………....………carbohydrate antigen 19-9 
IgG…………………………………………………………………………….. Immunoglobulin G 
LOD……………………………………………………………………............... limit of detection 
NaCl……………………………………………………………………………… Sodium chloride  
MgCl2………………………………………………………………............... magnesium chloride 
KCl……………………………………………………………………. ………Potassium chloride  
CaCl2…………………………………………………………………………….. calcium chloride  
CA 19-9 ……………………………………………………………….. carbohydrate antigen 19-9  
CFB ……………………………………………………………............... complementary factor B 
 
  xiii 
LIST OF SYMBOLS 
Kd…………………………………………………………………..…………dissociation constant  
M…………………………………………………………………………………………….. molar  
k ………………………………………………………………………………………………. kilo 
Da ………………………………………………………………………………………… Daltons 
L …………………………………………………………………………………………….. Liters 
C …………………………………………………………………………………............... Celsius  
nM ……………………………………………………………………………............... nanomolar 
M ……………………………………………………………………………………. micromolar 
L ………………………………………………………………………………………. microliter 
mL ……………………………………………………………………………………….. milliliter 
ng ……………………………………………………………………………………… nanograms 
picomolar ………………………………………………………………………………. picomolar 
nm ……………………………………………………………………………………… nanometer 
kcal …………………………………………………………………………............... kilo calories 
mol ………………………………………………………………………………………….. moles  
cm …………………………………………………………………………………….. centimeters 
s ………………………………………………………………………............... standard deviation  
m …………………………………………………………………………………………….. slope 
 
 
  1 
CHAPTER 1. INTRODUCTION 
 This chapter introduces many aspects of this research. Topics to be covered in this 
chapter include: carcinoembryonic antigen (CEA) as a protein and its uses as a biomarker 
combined with its application in therapeutics and diagnostics as well as CEA detection methods 
and how these methods can be improved. The possibility of improvement in reported method 
will be through the use of aptamers and the process by which these aptamers are designed is with 
SELEX. CEA aptamers have already been reported using an affinity SELEX, however, other 
SELEX methods have not been well studied. Therefor in this study two types of SELEX methods 
will be analyzed using CEA as a target molecule since it has also very widely used protein 
biomarkers.  
1.1. Background of Carcinoembryonic Antigen  
 Carcinoembryonic antigen, or more commonly known as CEA, is a glycoprotein that was 
first reported in 1965 by Gold and Freedman1. It was originally hypothesized that CEA was an 
oncofetal antigen, meaning that it is expressed specifically during fetal development while absent 
in healthy adults. CEA was then only re-expressed in the presence of cancers. However, this 
proved to be incorrect as it was then found to be expressed in healthy adult tissue2. This 
discovery opened up the possibility for CEA to become a potential biomarker.  
 The fact that CEA becomes elevated in the presence of cancer led to many studies being 
conducted on its gene family and structure. There have been 29 different genes/pseudogenes 
identified in the human CEA gene family. After further analysis, these genes were classified into 
three subgroups, the CEA subgroup, the PSG subgroup and a third subgroup3. CEA belongs to 
the immunoglobulin superfamily with two types of immunoglobin domains detected: the N-
terminal domain and the Ig variable domain4. It was determined that CEA bulk production takes 
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place in the colon, and was therefore hypothesized that CEA could be a viable biomarker for 
colorectal cancer. This lead to many studies have being conducted to evaluate the strengths and 
weaknesses of CEA as a biomarkers. 
1.2. Carcinoembryonic Antigen as a Biomarker 
CEA was first accepted in 1974 by the Food and Drug Administration (FDA) for the 
early detection of cancer, diagnosis of cancer and for the use in the regular screening of patients 
at high risk for the development of cancer5. However, additional studies have found that CEA 
levels become elevated in not only colorectal cancer, but also in liver, lung, stomach, pancreatic, 
and ovarian cancer6. Meaning, CEA has a very poor sensitivity toward colorectal cancer. Even 
though CEA does not show any specificity toward colorectal cancer, at least for early detection, 
it still has many uses. The most important use of CEA is utilized in the prognosis, monitoring 
and assessment of the follow-up treatment in colorectal cancer. It can also be useful in the 
monitoring ovarian cancer when CA 125 is not elevated7. Another use of CEA is as a predictive 
marker for the risk of recurrence and risk of death measured over time for lung cancer8. 
Regardless of not being selective toward colorectal cancer, CEA is one of the most extensively 
used clinical tumor markers. This could be for several reasons, such as: CEA is a stable 
molecule, has a restricted expression in normal adult tissues and is typically expressed at high 
levels in positive tumors9. Because of CEA’s versatility in monitoring certain diseases, it is not 
surprising it has been implemented in many analytical techniques and is of utmost importance in 
the implemented biosensors. 
Even though it has been proven that CEA offers poor sensitivity toward specific cancers, 
this does not rule out its usefulness in monitoring many diseases. There is also the possibility that 
CEA, in combination with other proteins, could offer a more selective prognosis panel for early 
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detection of cancer, but CEA should not be used independently. With this possibility, it vital that 
a CEA detection methods be explored.   
1.3. Introduction to Biosensors  
There has been much interest in biosensor research and development over the last fifty 
years, since the first medical biosensor was reported by Professor Clark at the New York 
academy of Science in 1962 by Professor Clark10. Biosensors have a wide application in the 
medical field for the detection of pathogens, genetic disorders and cancers. The medical 
biosensors developed, hope to improve the sensitivity and selectivity of assays, while 
maintaining the reliability of the test. An important implication of this type of test is to hopefully 
reduce the time required for execution as well as result analysis. The main goal of such medical 
biosensors is to create a home based preliminary screening for a wide range of diseases.  
 There are two main elements of a biosensor. The first is a form of a bio-recognition 
element that allows for the interaction of the target substance which then produces a readable 
signal. Without the bio-recognition element, there would be no readable signal output. Therefore, 
it is of the utmost importance that this bio-recognition element be selective toward the target to 
produce a specific test. The second main element is a transducer. There have been many reported 
transduces that produce results in optical, electrochemical and piezoelectric output signals.  
When a biosensor is in its most basic form, it utilizes a form of bio-recognition element that is 
oable to interact stringently and selectively with a target substance or molecule, after which the 
binding event is transduced to provide readable signal. As stated above, the goal of such medical 
biosensors is to make available simple to use, home based testing, which is why there have been 
many method for the detection of carcinoembryonic antigen.  
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1.4. Detection Methods of Carcinoembryonic Antigen   
Currently, the most reliable test for the measurement of CEA concentration in biological 
samples is with an ELISA test or an enzyme-linked immunosorbent assay. This type of method is 
often considered the gold standard in analytical chemistry and when testing a new method, it is 
not uncommon for the new method to be compared to an ELISA. In a typical sandwich assay of 
an ELISA, two antibodies are implemented. The first antibody, or capture antibody, is coated 
onto the surface of a well plate. When a target protein is present, it will bind with the capture 
antibody, while a secondary antibody will bind with the already bound protein, thus making a 
sandwich. On the secondary antibody, there is typically an enzyme present, that upon addition of 
a substrate, will induce a color change. This method is very useful since the darker the color 
change is, the higher the concentration of protein present, meaning the color is directly 
proportional to the amount of protein present in the solution. Other methods have been explored 
with the implementation of antibodies to detect CEA present in the solution. Some antibodies 
have been implemented in many analytical techniques such as electrochemical,11,12, 13 
fluorescent,14 chemiluminescent,15 label-free,16 and even colorimetric17. Even though there have 
been many successful implementations of antibodies for the detection of CEA, there are many 
drawbacks when using antibodies such as expensive to produce, each batch that is produced can 
provide some variations, difficult to upscale for large production purposes, unstable at various 
temperatures and pH thus making it difficult to modify and finally they have a limited shelf 
life18. It is because of these drawbacks that many researches are looking for alternative ways to 
detect proteins, thus turning their attention toward aptamers. 
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1.5. Potential Improvements toward Reported Detection Methods 
As stated before, there are many drawbacks when using antibodies, thus researches are 
now turning their attention toward aptamers. Aptamers are designed with SELEX or systematic 
evolution of ligands through exponential enrichment. Aptamers are single stranded RNA or 
DNA oligonucleotides and are fairly small in size and having a typical range from 20 to 60 
nucleotides18. Aptamers got their name from the Latin “aptus” meaning to fit19. This could not be 
a more appropriate name since aptamer can bind, or “fit,” to a large variety of targets including, 
but not limited to: simple inorganic molecules, complex proteins and even entire cells. It is 
because of this that aptamers are considered as nucleotide analogues of antibodies20. Not only do 
aptamers bind to a large range of targets, but an aptamer’s binding ability is considered to be 
comparable to antibodies. This is measured through dissociation constants(Kd) which have been 
reported for aptamers in the low nano-molar to high pico-molar range21. However, aptamers have 
many advantages over antibodies. The first is that aptamers are much easier and cheaper to 
produce than antibodies,20 because aptamers can be chemically synthesized. This process is well 
defined, highly reproducible, sequence independent, as well as can be easily up scaled for large 
production quantities, while the production of antibodies can require bacteria, cell cultures or 
animals, making the production of antibodies very time-consuming, and labor intensive22.  Not 
only is the production of aptamers easier, aptamers are also neither immunogenic nor toxic23. 
Finally, the last advantage is that aptamers are smaller than antibodies, resulting in better tissue 
penetration and faster blood clearance than antibodies24. It is because of these reasons that 
aptamers are ideal candidates for early diagnostic as well as therapeutic purposes. It is therefor 
not surprising that many aptamers have already been implemented in the medical field.   
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1.6. Aptamers Implemented in Therapeutics and Diagnostics Purposes  
There are many aptamers that have been implemented in therapeutics and diagnostics 
practices. For therapeutics aptamers have been implemented in many ways such as treatment of 
diseases, allergies, prevention of autoimmune disorders, and in the treatment of diabetes25. 
 One of the first FDA-approved aptamer for therapeutic applications is called Macugan in 
which the modified nucleotides were used: F-2’-fluoronucleotide, m-2’-O-methylnucleotide 
followed by being conjugate to 40 kDa polyethylene glycol or PEG26. The large PEG that is 
conjugated onto the aptamer stops nucleases. Macugen was first approved by the FDA in 2004 
and initially developed by NeXstar pharmaceuticals. Macugen as an aptamer that is used for the 
treatment of wet AMD or age-related macular degeneration, where macular degeneration is a 
disease that effects the eyes where there is an abundance of leaky blood vessels that can cause 
blindness in patients if the disease goes untreated. Macugen helps by binding to 165 isoform of 
vascular endothelial growth factor stopping the interactions with the receptors present on the 
blood vessels in the eyes, effectively stopping the excess growth of blood vessels, thus 
preventing blindness in the patient27. This is just one of the examples in how aptamers have been 
successfully implemented in the treatment of diseases. It can also be implemented in the help of 
treating allergic responses.  
A DNA aptamer was designed by the Mendonsa group in 2004 which can mask the 
allergic response28. In order to understand how this works it is necessary to understand how an 
allergic response occurs. For type 1 allergens, immunoglobin E (IgE) is involved in type 1 
hypersensitivity reaction. Type 1 allergens are mainly due to environmental factors such as grass, 
dust, pollens or food which then activates the immune system to over produce IgE antibodies. 
This overproduction can cause asthma, allergies and dermatitis. When the immune complex 
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binds to mast cell it can rupture the cell membrane releasing large amounts of granules which 
contains mediators such as histamine, serotonin, prostaglandins, and cytokines. These mediators 
are involved in smooth muscle contraction thus causing a hypertensive response29. This response 
can be stopped by the aptamer designed by Mendonsa which inhibits the interaction between the 
antibody and the mast cell, thus stopping the cascade effect.  Not only are aptamers used in 
helping with the allergic responses but it has also been used to prevent autoimmune disorders 
such as Systemic Lupus Erythaematosus (SLE). 
In the case of SLE is when auto-antibodies are generated against a persons own DNA, red 
blood cells and platelet membrane which can cause the lysis of the red blood cells leading to 
anemia as well as activate complement system that are involved in inflammatory responses and 
could cause tissue damage. Therefor, an RNA aptamer was selected to be against anti-DNA 
autoantibodies stopping the generation of antibodies30. This is just one example of how aptamers 
can be helpful in the treatment of autoimmune disorders. However, aptamers can also play a role 
in the treatment of diabetes.  
An RNA aptamer has been designed to help treat diabetes as it has been designed to bind 
to a murine insulin receptor antibody –MA20. The MA20 antibody destroys the insulin receptors 
of murine which can cause diabetes31.  When aptamer binds with MA20 it inhibits this process 
thus stopping the process of diabetes and thus stopping the damage of kidney. Another aptamer 
has known as NOX-E36 aptamer which targets chemokine CCL2, also stopping kidney 
damages32. These are just a few examples in which aptamers have been implemented in 
therapeutics, but aptamers have also been used for diagnostic purposes, such as for cancers. 
Aptamers have been implemented for the diagnostics of cancer as well as the therapy for 
cancer treatment. There have been FDA approved aptamers for the following targets such as 
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PDGF-r, pigpen, CTLA-4, Tenascin-C, Siayl Lewis X, PMSA, and nucleolin, proteins as shown 
in the table below. Each target has been helpful in different cancers and just shows the wide 
variety of protein targets.  
Table 1.  FDA Approved Aptamers for Proteins in Cancer 
Protein Target  Aptamer type  Role in Cancer  
PDGF-r DNA Platelet Derived Growth Factor Receptor (PDGF-r) is a 
tyrosine kinase protein involves in metastasis of tumor 
(36) 
Pigpen DNA Involved in blood vessel formation in cancer cells (37) 
CTLA-4 DNA Activated T cells further reduce the T cell response by 
raising threshold response needed for T-cell activation 
during cancer (38) 
Tenascin-C  DNA Activated during events such as fetal development, 
wound healing and in case of tumour growth (39-41) 
Siayl Lewis X  DNA Sialyl Lewis X is overexpressed in cancer cells and 
through selectin helps in metastasis process of cancer 
(42) 
PSMA DNA PMSA has high expression and activity in prostate 
tumour can be used as possible biomarker as well as 
target site for cancer treatment (43-47) 
Nucleolin DNA Recent studies have shown the presence of this protein 
on cell surface especially on cancer cells. (48,49) 
 
 
 As mentioned previously, there have already been aptamers identified toward CEA. 
Therefor the way in which these aptamers were identified will be discussed.  
1.7. Aptamers Identified Toward Carcinoembryonic Antigen 
 There have been two published patents for the aptamers specific toward CEA. The first 
was published in 2010 and has thus far had its aptamer implemented in more analytical papers 
and therefor will be the main-focus of this study. However, the other sequences are listed in a 
table below. C.L. Smith identified the first aptamer sequence specific toward CEA50 where the 
aptamer was designed using an already reported process by Ellington and Tuerk.19, 51 Briefly, a 
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random sequence library comprised of a greater than 1014 different sequences with primers 
flanking either side of the random sequence. Initially the CEA was incubated with a random 
DNA library and then immobilized within a 500 L Con-A column. The Con-A, also known as 
Concanavalin A which is a lectin and is able to bind to some sugar residues on some 
glycoproteins. Because of this, it is sometimes used to separate proteins that contain ceratin 
sugars from those that do not. The proteins containing the sugars can bind; whereas sugars that 
do not contain this will not bind. Once the proteins have been immobilized, the non-specific 
strands will be eluted. Since the specific strands will be in the column with the CEA protein. The 
non-specific strands are then discarded and then the CEA protein was then eluted. The proteins 
that bind to the concanavalin A can generally be eluted (detach) from the Con A by either 
changing the pH, the ionic strength, or by adding sugars that compete for the binding sites on the 
conA. In this case the CEA and aptamers were eluted with 0.5 M alpha-methyl-D-mannoside and 
0.5 M alpha-methyl-D-glucoside dissolved in binding buffer. These sugars disrupt the interaction 
between the CEA and the immobilized ConA on the column. Once the CEA was eluted, the 
DNA strands were separated with the use of a phenol. The DNA strands were then amplified 
with a polymerase chain reaction or PCR creating a new DNA pool in which the selection 
process was repeated as shown in figure 1.  
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Figure 1. Affinity SELEX Method 
For the identification of CEA aptamer this process was repeated 10 multiple times with 
positive and negative selection rounds were accomplished. After each round the library of 
aptamers that are specific toward CEA builds with a higher frequency of specific aptamers 
increases, as depicted in figure one.  
As stated, two negative selection rounds were accomplished. This was done to reduce 
cross reactivity. The negative SELEX method is done in the following manner where the DNA 
library produced from the first five positive selection rounds were incubated with some counter 
targets. These targets can be proteins with similar structures or common proteins found in real 
samples. Then the counter targets were conjugated into the column, however the sequences that 
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would not be selective toward counter targets would be the first eliminated from the samples. 
These eluted sequences were then incubated with the target of choice and was carried on as if in 
a normal SELEX round. The counter selection in SELEX is very important since it can play a 
large roll in diminishing cross reactivity.  
     
Figure 2. Negative Affinity SELEX Method 
For the CEA aptamer, this negative counter selection was accomplished a total of two 
times. At the end of the SELEX method, the DNA pool that was produced was sent for 
sequencing eliminating an aptamer with the following sequence: 5’ – ATA CCA GCT TAT TCA 
ATT – 3’ 
 This aptamer has been implemented in many analytical techniques which will be 
discussed in the following sections. 
  
Table 2. Reported CEA Aptamers 
Sequence  Reported  Used in Analytical Techniques 
5’ – TTT TTT TAT CCA AAG TTT TTT CGA ATA AGT – 3’  
5’- GCA GTT GAT CCT TTG GAT ACC CTG CTG – 3’  
  (52)  
5’ – ATA CCA GCT TAT TCA ATT – 3’  (50)   (53-58)   
5’- AAT TAA CCC TCA CTA AAG GGG AAT CCA ACT AAA CGT CCG – 3’  
5’ - ACC CTG CTA TAG TGT CAC CTA AAT CGT A – 3’  
5’ - GAC GAT AGC GGT GAC GGC ACA GAC GCC GCT ACC CCA TCC ACG 
CCA ATC CCG TAT GCC GCT TCC GTC CGT CGC TC – 3’  
5’ -  GAC GAT AGC GGT GAC GGC ACA GAC GCC CCA GGA AGA ACC 
TAC TCA CTG ATC GTA TGC CGC TTC CGT CCG TCG CTC – 3’  
5’ - GAC GAT AGC GGT GAC GGC ACA GAC GTC CCG CAT CCT CCG CCG 
TGC CGA CCC GTA TGC CGC TTC CGT CCG TCG CTC – 3’  
5’- GAC GAT AGC GGT GAC GGC ACA GAC GCC CGC ATC CTC CGC CGT 
GCT GAC CCC GTA TGC CGC TTC CGT CCG TCG CTC – 3’  
5’ - GAC GAT AGC GGT GAC GGC ACA GAC GAA ATC CCC GCT GAA TTA 
CCA CTT TAC GTA TGC CGC TTC CGT CCG TCG CTC – 3’   
5’ -  GAC GAT AGC GGT GAC GGC ACA GAC GCA CCG CTC TTA TGC CAC 
CAT TTT CAC GTA TGC CGC TTC CGT CCG TCG CTC – 3’  
5’ -  GAC GAT AGC GGT GAC GGC ACA GAC GAA TTG GGA GTT AGT ATA 
CAT CTT ACC GTA TGC CGC TTC CGT CCG TCG CTC – 3’  
5’ - GAC GAT AGC GGT GAC GGC ACA GAC GAT AGG GAG CAT TAC GTA 
ACC ATC TCC GTA TGC CGC TTC CGT CCG TCG CTC – 3’  
5’ – GAC GAT AGC GGT GAC GGC ACA GAC GTG TTC AGG ATC GAG GGT 
ATT TCT GTG CGT ATG CCG CTT CCG TCC GTC GCT C – 3’ 
 (59)   
1
2
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1.8. Carcinoembryonic Antigen Aptamers Implicated in Analytical Techniques  
As stated above, this aptamer has been implemented in many analytical techniques such 
as electrochemiluminescence,55, 57 electrophoresis53, fluorescence58 and colorimetric54. The 
colorimetric assay is what we will focus on since any new aptamers developed in this experiment 
will be first developed for a colorimetric method.  
 In this method, unmodified gold nanoparticles (AuNPs) were used as a transducer to 
indicate if CEA was present. The first took a thiolated aptamer as reported above as:   
5’ – ATA CCA GCT TAT TCA ATT –SH -  3’ 
This aptamer was dissolved in 0.1 M phosphate-buffered saline(PBS) to make a 10 M 
solution while 30 L aptamer solution with 15 L tris(2-carboxyethyl)phosphine (TCEP) was 
added to the samples containing different concentrations of CEA. It was then incubated for one 
hour at 37  C. This solution was then added to 500 L of AuNPs and incubated for one hour. 
The salt was added to induce a color change from red to purple. If there is not protein present in 
the solution the AuNPs will remain red since the aptamers in the solution should interact with the 
gold surface thus keeping it stable. However if the CEA is protein is present, then the aptamers 
should interact with the CEA since it has a higher binding affinity toward that protein. Then the 
aptamers should leave the gold surface, destabilizing it and thus allowing for it to aggregate54. As 
is shown in the figure below.  
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Figure 3. Colorimetric Method for the Detection of CEA Utilizing Specific Aptamer 
In this method, there had been finite success for the detection of CEA with a limit of 
detection of 3 ng/mL.  With a healthy cut off limit of 2.5 ng/mL, or 5 ng/mL, depending on the 
study being conducted this method provided a successful way in which CEA can be detected. 
This is an easy and simple colorimetric method that demonstrates that gold and be used to detect 
CEA in a solution with no modification. If an aptamer is designed with a new SELEX method an 
unmodified gold colorimetric method will be implemented.  
1.9. Aims and Objectives of the Study  
 There are multiple aims for this study. The first is to determine which method of SELEX, 
the affinity column versus the graphene oxide assisted, as to which would more efficiently 
separate the specific and non-specific strands. The second main objective is to try to improve the 
reported detection methods of CEA with the implication of new aptamer.   
 
 
  
15 
1.10. Significance of the Study  
 There is a great significance to this study, since there have been great strides toward the 
identification of aptamers in hopes that they can replace or work alongside of aptamers, however 
there have not been any studies that have directly compared multiple SELEX methods. 
Therefore, it is of great importance that this is accomplished so a higher quality of aptamers can 
be designed. There is also a great significance for the second aim of this study. This is because 
no CEA aptamer has been implemented in a POC platform for success. If this is accomplished, 
this could have a great impact in the medical field, since it could potentially be used in a 
diagnostic manner, as well as monitoring the disease, increasing the quality of life for sick 
patients.  
1.11. Limitations of the Study  
 There are a few limitations of this study. The first is that different personnel will be 
performing the two SELEX which means there could be some irregularities when performing the 
experimentation. Another is that the results from this experimentation will not be fully 
conclusive since this is the first study that has been accomplished. Therefor more experiments 
will have to be conducted.   
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CHAPTER 2. DEVELOPMENT OF CARCINOEMBRYONIC ANTIGEN APTAMERS 
UTILIZING GRAPHENE OXIDE ASSISTED SELEX 
2.1. Literature Review of SELEX  
Systematic evolution of ligands through exponential enrichment also known as SELEX, 
is used to identify aptamers. Aptamers, as introduced in the previous section, are classified as 
synthetically made, short single stranded sequences of DNA or RNA60. The SELEX process was 
first identified by two independent research groups. One group identified this process when 
designed RNA ligands to bind with bacteriophage T4 DNA polymerase51 while another group 
designed RNA molecules that would bind specifically to certain ligands19.  
A positive outlook on SELEX is that it is not limited to a certain type of target. Aptamers 
have been identified for targets including proteins, heavy metals, bacteria and cells. Once 
aptamers have been identified, they are considered to be very specific and selective toward their 
intended target61. It is because of aptamers ability to bind specifically and selectively toward a 
certain target, that significant interest has been given toward aptamers and their design.  
 Since first described in 1990 many variations of the SELEX method have been made, 
some include using capillary electrophoresis (CE)62, surface plasma resonance (SPR)63 , mirco-
free flow electrophoresis64, as well as an automated method 65, 66 and even MonoLEX or a one-
step aptamer protocol67. Some of these methods were described in the previous section showing 
how the SELEX process has been improved to limit the time and labor to complete this 
experiment.  
 Now, depending on the cost and the instrumentation available, this can place a limit on 
which method is used. There are many approaches to identifying aptamers, the one to be utilized 
in this study is known as graphene oxide assisted SELEX. This method is very like the similar to 
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the general outline of SELEX process where the starting random nucleotide library is incubated 
with the target, however to aid in the separation of bound strands from unbound strands, 
graphene oxide is added. The graphene oxide is added because it can effectively absorb DNA 
strands on its surface through - stacking68. After the separation is completed, the process 
continues as a typical SELEX method44. This is depicted below as graphene oxide- SELEX or 
GO-SELEX.  
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Figure 4. Graphene Oxide Assisted SELEX 
As shown in the figure above, the method is based on, a counter selection round which is 
also shown.  A counter selection round or negative selection round, is commonly used to ensure 
an even more selective and specific aptamer. This is done by using the DNA pool that has been 
generated from the positive selection rounds and incubated with targets that closely resemble the 
  
19 
target. This gives any strands that are specific toward the counter target, a chance to bind while 
the specific strands toward the target will stay in solution. By the addition of graphene oxide into 
the solution, the specific strands will interact and allow for the discard of the non-specific 
strands. Then the target is added into the solution containing both the graphene oxide and 
specific strands. These strands should have a higher binding affinity toward the target than 
toward the graphene oxide. Thus, the strands with a high specificity toward the target will leave 
the graphene oxide and bind to the target. The SELEX process then continues as a typical 
positive selection round. This counter selection is necessary so the aptamers that are developed 
have less cross reactivity, thus leading to a higher quality aptamer. In this experiment, both the 
positive and negative selection process will be implemented to design an aptamer. Once the 
aptamers have been designed, the most appropriate aptamer will have the most repeats after 
sequencing. 
In this experiment, the two different types of SELEX will be compared while using CEA 
as a model protein. From here, it can be evaluated based on whether there have been 
improvements to the initial SELEX process as first described in 1990, as well as if the graphene 
oxide acts as a sufficient separation method.  
2.2. Materials and Methods  
2.2.1. Materials and Instrumentation for the Graphene Oxide SELEX Experiment 
The following sources were used for purchase of materials used in this experiment were 
purchased from the following. The native carcinoembryonic antigen protein was purchased from 
Fitzgerald, while the trizma hydrochloride and phenol-chloroform-isoamyl solution was 
purchased from Sigma Aldrich. The primers and random nucleotide library were purchased from 
integrated DNA technologies and have the sequences as the following:  
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Random Library Sequence:  
5’- ATC CAG AGT GAC GCA – NNN`30- TGG ACA CGGTGG CTT AGT - 3’ 
Forward Primer:  
5’ - Alex488N/ ATC CAG AGT GAC GCA GCA – 3’  
Reverse Primer: 
5’ - BiosG/ ACT AAG CCA CCG TGT CCA – 3’  
The dNTPs and Taq polymerase that were used for the polymerase chain reaction were 
purchased from New England Biolabs. The NAP- 5 columns, Sephadex G-25 DNA grade was 
acquired from GE Healthcare and the streptavidin agarose resin from Thermos Scientific. After 
each round of selection, the ssDNA the concentration was measured on a NanoDrop 2000c 
Spectrophotometer.  
2.2.2. Graphene Oxide Assisted SELEX 
The graphene oxide assisted SELEX was used to design aptamers for CEA. The aptamer  
was designed using a method that was previously reported69. Briefly for the positive SELEX 
round, 200 pmoles of a random nucleotide library were dissolved in 20 mM Tris HCl with a 
pH=7.4 and placed in a water bath of 95 C for five minutes, followed by an immediate 
placement in ice for fifteen minutes. Then, the ssDNA was incubated in equal concentration of 
CEA protein for one hour on ice with a gentle mix allowing for any specific strands to bind to 
the protein with the non-specific strands in the solution. Then graphene oxide was added to make 
a ratio of 1:8000, ssDNA to graphene oxide. This was incubated for another hour on ice with a 
gentle mix. The non-specific strands should then interact with the graphene oxide surface which 
can effectively absorb the DNA on its surface through -  stacking68. This made it very easy to 
separate the specific strands from the non-specific strands. Upon this the sample was centrifuged 
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for fifteen minutes at 13 krpm in effectively separating the two, which allowed for the collection 
of the specific strands and the protein in the solution. To separate the protein from the bound 
DNA, an equal volume of phenol-chloroform-isoamyl was added. It was the shortly centrifuged 
to create two layers in which the top was collected containing the ssDNA. To conclude this 
round of selection, an ethanol precipitate was performed following a polymerase chain reaction 
to amplify the DNA. After the PCR the sample was double stranded but in order to start the next 
round the DNA must be converted into a single strand. This is why the reverse primer was 
tagged with a biotin. It was with this that when an affinity column is utilized, it causes the biotin 
to bind to the streptavidin which will then bind, thus when washed with sodium hydroxide, it will 
cleave the hydrogen bounds, thus washing out the forward strand, which can be used in the next 
round as is depicted is Scheme 1. After each round of selection, a nano-drop reading was taken 
to calculate the amount of DNA recovered after each round.  
 
Scheme 1. Graphene Oxide Assisted SELEX showing Positive and Negative Selection 
Rounds  
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To reduce cross reactivity, there were multiple negative SELEX rounds accomplished. 
This process was repeated in a manner like that of the positive SELEX round in which 200 
pmoles were incubated with protein of equal amounts. However, the protein in the negative 
selection round was carbohydrate antigen 19-9 (CA 19-9), bovine serum albumin (BSA), 
mammaglobin, and immunoglobulin G (IgG). This followed the positive selection round for 
when graphene oxide was added the strands specific toward CEA was interacted with the 
graphene oxide. The counter targets were then separated by centrifugation. The graphene oxide 
was then re-suspended in a solution containing 200 pmoles of the CEA, the DNA interacting 
with the graphene oxide would leave the surface and bind with the target protein since these 
strands should have a higher binding affinity toward the protein, in which the round continued as 
a positive SELEX round. This process is also depicted in Scheme 1. The total number of rounds 
performed of this was ten, accounting for seven positive rounds and three negative rounds. After 
the tenth round of selection the aptamers were then sent to the University of Florida for the Next 
Generation Sequencing given four potential aptamers. One of these aptamers where studied 
further to determine their dissociation constant with the use of surface of plasmon resonance 
(SPR), to be discussed in the following chapter.  
2.3. Results 
After each round of selection, a nano-drop reading was performed, and the percent of 
DNA recovered is shown in the following figures. In the figure 5, all rounds of selection were 
shown while in the sixth figure shows only the positive rounds of selection so that a trend can be 
accurately measured.  In figure 5, the red boxes around the rounds, 6, 8 and 10 indicate that these 
were the negative selection rounds.  
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Figure 5. Percent of DNA Recovered from all Selection Rounds 
While figure 6 just shows the percentage of DNA recovered from the positive selection 
rounds and is how it was determined to send the DNA pool for sequencing.  
 
Figure 6. Percent of DNA recovered for all Positive Rounds 
After the tenth round of selection with very little change in the percent of DNA 
recovered, the DNA pool was then sent to the University of Florida for sequencing using Next 
Generation Sequencing. From this, four potential aptamers were identified and provided in the 
table below.  
0
10
20
30
40
50
60
70
80
1 2 3 4 5 6 7 8 9 10
P
er
ce
n
t 
o
f 
D
N
A
 R
ec
o
ve
re
d
Number of Rounds
Percent of DNA Recovered after each round
0
10
20
30
40
50
60
70
80
P
er
ce
n
t 
o
f 
D
N
A
 R
ec
o
ve
re
d
Number of Positive Rounds
Percent of DNA recovered after each positive 
round
1           2           3           4           5          7         9      
  
24 
Table 3. Aptamers Identified with GO-SELEX 
 
 Sequence 
CEA Apt 1  5’ – GGA ATC GGT GGC TTC ATG CTA GTC GCG GGC – 3’  
CEA Apt 2  5’ – GCA GGG GTT TAA ATT GAC GAC TTA TCA CTG – 3’  
CEA Apt 3  5’ – CCC TGC ACT ATC CTA TTC GAA TTG TTC CTG – 3’  
CEA Apt 4  5’ – CGA AGT TAC GCT AGT CGG ATA CAA TTC TGGT – 3’  
 
 Aptamers one had the most repeating sequences and thus will only be studied further to 
determine the dissociation constant.  Of these aptamers that have been isolated, none match the 
reported CEA aptamers from other papers.  
2.4. Discussion  
After each round of selection was accomplished, a nano-drop reading was done to 
evaluate the percent of DNA recovered. After round two, a sufficient amount of DNA was 
eliminated due to the graphene oxide separating the specific from the non-specific strands. Upon 
evaluating all rounds, it became apparent that the negative rounds of selection was not 
eliminating the DNA as efficiently as the positive selection rounds. Meaning, most of the DNA 
produced from the first five rounds of selection produced many DNA strands that were specific 
toward CEA. This is shown in figure five where the negative rounds are shown in the red boxes. 
As shown in figure six, there seemed  to not be much change in the percent recovery from rounds 
seven to nine, even with a negative round in-between to indicate that most of the non-specific 
strands have been eliminated and that was ready for sequencing. Evaluating the results from the 
NextGen Sequencing, it became apparent that one of the four strands would be better suited for 
further investigation since the frequency in which aptamer 1 appeared is 7-10 times the amount 
of aptamers 3 and 4 and almost twice as often as aptamer 2. Therefor by accounting the number 
of repeated sequences, aptamer 1 is the only aptamer used in future experimentation.  
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2.5. Conclusion  
 In conclusion, based on the frequency of aptamers found by NexGen Sequencing, 
aptamer one is the only aptamer that will be further analyzed in future experiments and what will 
be used for the comparison for the GO-SELEX to the affinity SELEX, as that aptamer was 
mentioned in chapter one. This comparison of the two methods will be accomplished by finding 
the dissociation constant with surface plasmon resonance (SPR). This will be done in the 
following chapter.  
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CHAPTER 3. DETERMINATION OF DISSOCIATION CONSTANTS WITH SURFACE 
PLASMON RESONANCE 
3.1. Literature Review of Methods for the Determination of Dissociation Constant  
 The dissociation constant is a specific type of equilibrium constant that measures the 
propensity of how a ligand can bind to a certain target and is the inverse of the association 
constant.  This value is very important because it can quantify the quality of the aptamer and its 
ability to bind to its targets. Since this value is of great importance it is not surprising that many 
methods have been developed to determine this value. Some of these common methods would 
be; isothermal calorimetry(ITC), surface plasma resonance(SPR), electrophoretic mobility shift 
assay(EMSA), and fluorescent anisotropy.  These methods will be explored, as well as the 
advantages and disadvantages discussed.  
  A common method is isothermal calorimetry or ITC. ITC experiments are performed 
using  incremental titration where a precise volume of titrant is added to a solution of titrand at 
specific time intervals70. When the ligand binds to the target it releases or absorbs heat in direct 
proportion to the amount of binding that occurs71. This can produce a variety of peaks in which 
the area under each peak is integrated and then normalized to fit a model that allows for the 
calculation of affinity, enthalpy and the stoichiometry for the interaction70. There are many 
advantages to using ITC, the main is that it can provide a nearly complete thermodynamic 
characterization of an interacting system under one set of conditions72. These conditions being; 
standard state binding free energy (G), binding enthalpy (H), and binding entropy (S) and 
are related by the equation below:  
ΔG° =  −𝑅𝑇𝑙𝑛𝐾𝑒𝑞 =  ∆𝐻 − 𝑇∆𝑆° 
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Some other advantages is that it does not require immobilization and/or modification of 
protein or ligands since the absorption or production of heat is an intrinsic property of virtually 
all biochemical reactions73. The final advantage for this method is that this technique is relatively 
easy to perform71. However, there are some major draw backs to this method such as it can 
require a large amount of protein. This can mean that any concentration that is lower than high 
nano-molar is not sufficient to generate a significant injection heat signal and then the thermal 
gram is too shallow to be meaningful. This means that a high nano-molar sample concentration is 
chosen with a low pico-molar Kd binding system. This can lead to a steep titration curve with 
few points, thus giving rise to a large error in the dissociation constant74. This is just one of the 
methods that have been developed however another methods have been developed without the 
use of heavy instrumentation one of these methods is electrophoretic mobility shift assay.  
 The electrophoretic mobility shift assay, or EMSA, is done with the use of native gels 
because it can monitor the migration of DNA. When DNA becomes bound to a protein its 
molecular weight changes, thus slows the rate in which DNA migrates through the gel. When 
there is no protein bound, the DNA is fairly light in molecular weight, thus will travel the 
furthest through the gel, however, upon the binding of protein there will be a change in weight, 
and thus the DNA cannot travel as far as it had without the protein. From this, the dissociation 
constant can be determined from the amount of unbound and protein bound DNA in the gel78.  
This method is very popular because it is a highly sensitive, and low cost. However, this 
method has many drawbacks, the first is that it is very time consuming, taking 30 min to several 
hours depending on how long it takes to separate the bound from the unbound DNA. The other is 
that the dissociation is usually much slower than predicted based on solution measurements and 
distinct bands are obtained74. The final drawback of this method is that it typically uses a 
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radioactive label, thus making it dangerous to work with and can increase the cost of the 
experiment to discard the waste properly79. Even with these draw backs, EMSA is generally a 
more appropriate assay for the initial characterization of protein to ligand interaction, if binding 
is observed, experimental conditions can be optimized or another method can be used80. Another 
method that can be utilized is using fluorescence anisotropy intensity.  
 Fluorescence anisotropy is when there is light that is emitted by a fluorophore that will 
emit unequal intensities along the difference axes of polarization. When a ligand binds with 
protein or target present, there can be a change in fluorescence anisotropy. In most cases, the 
DNA is labeled with a fluorophore and the DNA will be emitting different light down different 
axes at a faster rate. Upon binding, the fluorophore starts rotating at a slower rate, thus increasing 
the fluorescence anisotropy. There are many advantages to using this method over the other 
methods mentioned. The first is that the use of fluorophores do not require special licensing and 
has no extra cost for the disposal of radioactive waste, unlike EMSA. The other is that these 
measurements only require a minuet amount of targets and oligonucleotides because the 
sensitivity of fluorescence, unlike ITC which requires a much larger amount of protein/target. 
The other is that this method does not require a step such as filtration or electrophoresis to 
separate the free or bound ligands. This may yield more true equilibrium binding constants79. 
This method, like most methods for determining the dissociation constant has a few 
disadvantages, some being that expensive equipment, is required using a fluorophore-labeled 
oligonucleotide is that the fluorophore label are typically large enough that they could potentially 
interfere with or otherwise influence binding. Therefor another method has been developed 
without the use of the fluorophore so this interference will not happen, an example of this 
method is the surface plasmon resonance.  
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Surface plasmon resonance (SPR) is special electromagnetic modes which may exist at 
the surface of a metal. The SPR works in the following manner, some polarized light will hit a 
metal film in which the interface of media will have a difference in refractive indexes. This will 
excite and detect the collective oscillations of free electrons, or surface plasmons, on the surface. 
This is accomplished with Kretschamnn configuration. This is where light is focused on the 
metal film through a glass prism and thus the reflection is detected. This change in refractive 
index can cause a dip in the reading and can be used for the determination of the dissociation 
constant by evaluating the shift in the reflectivity curve. This is done by monitoring the shift of 
the resonance vs. the time75. The advantages to using SPR, includes that it is a label free 
detection, the experiment can be accomplished within twenty minutes. The label free detection 
can help with the determining of both the thermodynamic and kinetic information76. However, 
whenever using this method caution should be employed. This is to ensure that the mass transfer 
of the protein from the bulk solution in the flow cell to the aptamers on the surface of the SPR. 
This can slow the observed association rate and give rise to an underestimation of the 
dissociation constant77. It is because of these drawbacks that in most cases it is necessary to 
perform binding studies with two different methods.  
Speaking from a direct biochemistry background, the dissociation constant should be 
constant no matter what method is being implored. However, there can be many factors that will 
influence value, especially if the experimental conditions were not optimized such as: the type of 
buffer used for the experiment as well as the type of tag used on the aptamer, if the aptamer is 
free floating in solution and finally the sensitivity of the method could all lead to different 
dissociation constants being reported. This became clear in the reported aptamer. The reported 
aptamer had the dissociation constant calculated with two different methods. In method one they 
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choose to use EMSA and had a dissociation constant of 10-6 M, while the other method used was 
fluorescent anisotropy reading which found the dissociation constant to be ~ 10 nM50. It is 
therefore not uncommon to have two different dissociation constants reported when doing these 
studies and so when comparing the binding, the same method will have to be accomplished to 
ensure that a proper comparison can be accomplished. In this study, a surface plasmon resonance 
will be accomplished for the aptamer that was isolated in the graphene oxide assisted SELEX 
while the same method will be done on the reported aptamer.  This study will help determine 
which aptamer binds more tightly toward the CEA target and thus allows for the quality of the 
aptamer to be determined.  
3.2. Materials and Methods   
3.2.1. Materials  
The materials used in this experiment were purchased from the following companies: the 
HEPES, magnesium chloride, biotinylated BSA and TWEEN were all purchased from Sigma 
Aldrich. The streptavidin covalently immobilized on a carboxymethyl dextran surface gold chip 
in which all the experiments perform was obtained from Reichert and the CEA protein was 
purchased from Fitzgerald. The two biotinylated DNA was purchased from integrated DNA 
technologies which were aptamer one that was identified in the previous chapter and the aptamer 
that was identified in other works. Both aptamers have been modified with a biotin on the five-
prime end and the sequences as follows:  
Aptamer One:  
5’ - /5Biosg/GGA ATC GGT GGC TTC ATG CTA GTC GCG GGC – 3’ 
Reported CEA Aptamer:  
5’ - /5Biosg/ ATA CCA GCT TAT TCA ATT – 3’  
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All the experiments were performed on two channel Reichert 2 SPR and the data were 
analyzed using scrubber software, in which the dissociation constant was calculated.  
3.2.2. Method of Conjugation 
 As stated above, the biotinylated aptamer was easily conjugated onto the surface of the 
gold chip. However, the method for the conjugation of the aptamers on the gold surface were 
different than how the dissociation constant was determined. The biotinylated aptamer was 
added under the following conditions: 250 L injection of 50 nM biotin-aptamer followed by a 
five-minute dissociation and two wash cycles of 500 L with a wait for one minute while 
keeping the infuse rate constant at 25 L/min. This was done for both aptamer one isolated from 
chapter two and the reported aptamer in chapter one.  
3.2.3. Dissociation Constant Titration and Determination  
 The way in which this experiment was conducted was done by the following scheme. 
Initially started with a gold chip that had streptavidin immobilized on a carboxymethyl dextran 
surface. Then there was 50 nM of biotinylated aptamer injected and would interact with the 
streptavidin on the gold surface. The addition of the biotinylated aptamer was only performed on 
the left channel since to the refractive index and peak intensity is found by taking the difference 
between the two channels. However, once the biotinylated aptamer was conjugated onto the gold 
surface, the following were done to both channels. Then 50 mg/mL of biotinylated BSA was 
added followed by a three hour incubation of BSA to block the excess streptavidin binding site to 
reduce non-specific binding for the CEA. The chip was then washed three times with running 
buffer containing 40 mM HEPES, 10 mM MgCl2 and 0.005% TWEEN. This was to get rid of 
excess, non-bound BSA. Finally, different amounts of CEA was then added onto the chip. Since 
  
32 
CEA bound so quickly toward its aptamer it did not need a regeneration buffer, instead it was 
washed more with the running buffer. This is depicted below.  
      
Scheme 2. Representation of Surface Plasmon Resonance Experiment 
The parameters that were ran on the SPR for the measurement of the dissociation 
constant determination was programed as follows: 250 L of the protein sample was injected 
over a span of four minutes followed by a five minute dissociation then the chip was regenerated 
with a 100 L of running buffer for thirty seconds followed by a one minute dissociation. This 
was followed by two 500 L wash cycles while the infuse rate was kept at a constant of 5 
L/min. This was kept constant for all samples taken. For aptamer one the concentrations 
evaluated were 75 nM, 125 nM, 250 nM, 750 nM and 1 uM of CEA and for the reported aptamer 
the concentrations measured were 750 nM, 1 M, 2 M and 3 M.  
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3.3. Results 
  To ensure that the aptamer has indeed bound to the left side of the channel a certain trend 
must be observed as shown below. This was accomplished because of the binding between the 
biotin and streptavidin.  
 
Figure 7. Proof of Conjugation of Aptamer onto the Gold Surface  
The way in which the raw data was evaluated was performed on the Scrubber software. 
This was done by first zeroing out the initial peaks since that was caused by some background 
noise, it then was fitted with the curves. An example of this is shown in figure eight. This was 
accomplished for every experiment since it was done in triplicate for the aptamer that was 
isolated in the graphene oxide assisted SELEX method as well as for the reported aptamer from 
the affinity method.  
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Figure 8. Aptamer One Curve Fitting in Scrubber Application of Raw Data for the 
Calculation of Dissociation Constant 
These experiments were performed in triplicate in which the calculation of the 
dissociation constant was also accomplished three times. The average of this was done in the 
table below and had a dissociation constant calculated to be 253.68  15.75 nM. 
Table 4. SPR Determined Dissociation Constant for Aptamer One 
 
Experiment Dissociation Constant (nM) 
1 235.64 
2 260.17 
3 264.68 
Average 253.68 
Standard Deviation 15.75 
 
Another way to evaluate the data is to manually the plot the raw data and evaluate the 
peak intensity at a specific time. From this curve, a dissociation constant can be estimated. The 
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experiment was repeated three times with the concentrations of 75 nM, 125 nM, 250 nM, 750 
nM and 1 uM of CEA. The peak intensities were then averaged and plotted to produce the graph 
below.  
 
Figure 9. Curve fitting of the SPR Data to Calculate the Dissociation Constant for Aptamer 
One 
After aptamer one was evaluated, the reported CEA aptamer was also accomplished in 
the same manner as aptamer one and also accomplished in the Scrubber software.  
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Figure 10. Reported Aptamer curve fitting  in Scrubber application of Raw Data for the 
Calculation of Dissociation Constant 
 Based on the curve fitting, in the Scrubber application, three dissociation constants were 
calculated as shown in the table below in which these were averaged and had the standard 
deviation calculate. This allowed for the dissociation constant to be determined to be 828.26  
23.99 nM.  
Table 5. SPR Determined Dissociation Constant for Reported Aptamer  
 
Experiment  Dissociation Constant (nM) 
1 831.57 
2 850.43 
3 802.79 
Average 828.26 
Standard Deviation  23.99 
 
Not only was the data evaluated in the Scrubber application, the data was also examined 
in excel in which the data was plotted manually when the peak intensity was taken and plotted 
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against the concentration. In this case for the reported aptamer, there was no plateau until 2M. 
The concentrations that were evaluated were 0.75, 1, 2, and 3 M as shown in the figure below.  
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Curve Fitting of the SPR Data to Calculate the Dissociation Constant for 
Reported Aptamer 
3.4. Discussion  
 This experiment first goal was to make sure that the aptamer identified in the previous 
chapter was indeed binding to carcinoembryonic antigen. The quality of the aptamer could be 
actively measured through the dissociation constant. For this experiment to be successful the 
aptamer need to be conjugated onto the gold surface therefor the first part of this experiment was 
to see that the aptamer was indeed binding to the gold chip surface. This was evaluated in figure 
seven. By seeing the large change in the response, and that the change was constant there 
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indicated that the biotin and streptavidin has bound and thus has successfully bound to the 
surface making the rest of the experiment possible.  
 Once the aptamer was conjugated on the gold surface the different concentrations of CEA 
were evaluated on the SPR, with an increasing concentration there was an increase in the 
response. The data was evaluated in two different ways. The first was on a software application 
called Scrubber in which the dissociation constant was calculated. The experiment was repeated 
three times giving three different dissociation constant values however the average of these were 
253.68 15.75 nM. This indicated that the CEA is binding to the aptamer fairly-tightly since 
aptamers have been reported to bind to their proteins from low micromolar to high picomolar 
range74. Another way in which the dissociation constant was estimated is by evaluating the 
michaelis-menten curve and taking half the VMAX and seeing the KM. The KM is roughly 250 nM 
which corresponds to the calculated dissociation constant. It was confirmed that this dissociation 
constant was correct. This indicates that aptamer one is binding to CEA and thus is more likely 
to work in future biosensors.  
Another goal of this experiment is to directly compare the aptamer that has been 
identified in the graphene oxide SELEX to the reported aptamer that has been identified in the 
affinity SELEX method. This was also accomplished in this study. A reported aptamer as also 
had a dissociation constant reported for it however, neither had a SPR done. The aptamer had a 
dissociation constant that was reported in the 10-6 M when used using electrophoretic mobility 
shift assay (EMSA) and in the low nanomolar range when using fluorescence anisotropy50. These 
each have some drawbacks since EMSA is not very sensitive while fluorescence anisotropy 
while being sensitive and being free floating in solution, the fluorescent tag can interact with a 
hydrophobic pocket thus providing a false dissociation constant. In this study, the reported 
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aptamer experiment was accomplished in the same manner as the aptamer identified in the 
previous chapter. However, more protein was needed to finish the titration and thus the aptamer 
had a dissociation constant that was calculated to be 828.26  23.99 nM. This is significantly 
higher than the dissociation constant that was calculated in for aptamer one that was isolated in 
the graphene oxide assisted SELEX. This is an indication that aptamer one binds much more 
tightly to CEA than the reported aptamer.  This value that was calculated for the reported 
aptamer was properly done by using the Scrubber application in which the data was fitted, along 
with the curve allowing for the calculation of this dissociation constant as shown in figure ten. 
This constant was also verified by plotting the raw data and taking the half of the VMAX and 
visually seeing the KM allowing for an estimation of the dissociation constant. By looking at the 
graph in figure 11, one could estimate the dissociation constant to be roughly 850 nM. This 
corresponds with the calculations that were completed indicating that this was done correctly. 
However, this value could be improved.  
To confirm that the aptamer one is indeed better than the aptamer previously reported, 
another dissociation constant experiment could be accomplished with other methods mentioned 
previously such as ITC, EMSA or fluorescence anisotropy. There could also be improvements to 
the SPR experiment. This could be done by possibly by using a different gold chip surface in 
which the aptamer could be thiolated onto the gold surface and decrease the background noise 
thus lowering the dissociation constant. Another way is to by adding a 15 poly adenine to the 
five-prime end of the aptamers, thus increasing the distance between the gold surface and where 
the interaction takes place on the protein. This could allow for the aptamer to form its 3D 
configuration better and thus could possibly improve the dissociation constant.   
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3.5. Conclusion  
 In conclusion, this experiment was very successful in the determination of the 
dissociation constant for both the reported aptamer and the aptamer isolated in the previous 
chapter. The dissociation constant for the reported aptamer was found to be 828.26  23.99 nM 
while the aptamer isolated with the graphene oxide assisted SELEX was found to be 253.68 
15.75 nM. This indicates that the aptamer isolated from the GO-SELEX binds more tightly to 
CEA than the aptamer isolated from the affinity-SELEX, thus graphene oxide can sufficiently 
separate the specific from the non-specific strands indicating that this GO-SELEX could be used 
for future experiments.  
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CHAPTER 4. UTILIZATION OF UNMODIFIED GOLD NANOPARTICLES FOR THE 
COLORIMETRIC DETECTION OF CARCINOEMBRYONIC ANTIGEN 
4.1. Literature Review of Gold Nanoparticles  
 Gold nanoparticles or AuNPS are very common nanoparticles that are employed in 
aptasensors. The reason for this is that they offer many advantages such as ease of synthesis and 
surface modifications, strongly enhanced and tunable optical properties and finally have 
excellent biocompatibility feasible for clinic settings81. This is because AuNPs are the most 
stable of metal nanoparticles and has a long history. Gold extraction started around the 5th 
millennium B.C. near Bulgaria while by the 1200-1300 B.C. Egypt was extracting roughly 10 
tons per year. Soluble gold appeared around the same time that extraction took place, either the 
5th or 4th century B.C. in Egypt and China and was used in but aesthetic and curative properties82. 
From here there has been much exploration on how to make and use gold for benefit. Therefor it 
is not surprising that there have been many advancements in the synthesis of AuNPS such as 
different shapes and structures, these include: nanorods, silica/gold nanoshells, and hollow 
AuNPS83-85. These wide range of shapes help employ gold into many techniques. However, the 
there is a large question as to why the gold can give off such a large range of colors. This 
originates from a basic photophysical response that is not observed in nonmetallic particles. 
When this metal is exposed to light, it will induce a collective coherent oscillation of free 
electrons of the metal and will cause the particles on the surface to a charge separation with 
respect to the ionic lattice. Thus, forming a dipole oscillation along the direction of the electric 
field of the light. The amplitude of the oscillation will reach a maximum at a specific frequency, 
this is called surface plasmon resonance or SPR as mention in section 1.6 Dissociation 
Constants86-90. The SPR induces a strong absorption of the incident of light and can be measured 
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with a Ultra Violet -Visable absorption spectrometer. This band that the SPR reproduces is much 
stronger in plasmonic nanoparticles, such as gold and silver, than other metals. The band 
intensity and wavelength is dependent on many factors such as: metal type, particle size, shape, 
structure, composition and the dielectric constant of the surrounding medium91. Essentially the 
color that is produced by gold reflecting the red light or ~700 nm while the gold nanoparticles 
absorb the light of the blue-green portion of the spectrum or roughly ~450 nm. Since the gold 
nanoparticles reflect the ~700 nm, an observation of a red color will be seen. This is one of the 
main advantages in using gold since it can indicate a bright red color that can be easily seen.  
 Another advantage is that gold can be easily synthesize, one method that is most common 
is called the citrate reduction method. This method was first introduced in 1951 by Turkevitch 
and essentially reduces gold(III) using citrate reduction of HAuCl4 in water
84. However, this 
method does not provide a specific size but by variation of the ratio between the reducing and 
stabilizing agents, gold nanoparticles can be made to a prechosen size between 16 and 147 nm92. 
A variation of this method is used in this study to make gold nanoparticles.   
The ease in which gold nanoparticles have a surface modification is a main reason why 
gold is implemented in a wide range of techniques which have been introduced in previous 
sections.  There are two main ways in which DNA can be conjugated onto the gold surface, these 
are: absorption, amine coupling via reactive esters, while the third would be layer-by-layer. 
In the first where absorption is utilized, gold is considered a self-assembly monolayer 
(SAMs) and covered in hydroxyl and thiol groups, in which the a sulfur will directly absorb onto 
the surface of the gold and create a thiol bond. The bonding of this exploits a strong dative bond 
with a strength that measures roughly 40-50 kcal/mol which is comparable to that of a gold-gold 
bond93,94.  This method is typically done as shown below: 
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Figure 12. Aptamer Thiolated onto a Gold Nanoparticle Surface 
This provides a chemically stable and functional nanoparticle as well as an ease in 
synthesis therefor it is regularly used. However, it is not the only method and if a stronger bond 
is desired a different method is used. 
A method in which a stronger bond is observed is one in which a covalent bond is 
produced and is accomplished through the amine coupling via reactive esters. However there a 
multiple ways in which this is accomplished and depending on how the AuNPs will be modified 
there are different functional groups adhered to the surface of the gold. Take for instance if a 
protein was to be conjugated to the surface of the gold, for this to be possible the surface of the 
gold is coated in a hydrophilic three-dimensional non-cross linked carboxymethylated polymer, 
making biological reactions to occur in water. This polymer will have a carboxylic acid on its 
tail. At this point is where the conjugation of the aptamer as long as the aptamer has been 
modified with an amine group95.  
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Figure 13. Aptamer Covalently Conjugated onto a Gold Nanoparticle Surface  
Even though gold nanoparticles can be easily modified for the use of analytical testing, 
this is not always necessary. In many cases there has been no need for gold modification for the 
detection of many types of targets including: 17-estradiol,96 metal ions97,98 adenosine 
triphosphate99 and proteins54,100 .   
For these methods are performed in a similar manner. The unmodified gold nanoparticle 
is incubated with an aptamer that is specific toward the target and will interact with the gold 
nanoparticle surface. When target is added the aptamer should interact with the target leaving the 
gold surface open for the salt to interact with the surface allowing for the aggregation of gold 
nanoparticles leading to a color change as depicted below101.  A variation of this method will be 
implemented in this study.  
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Figure 14. Unmodified Gold Nanoparticle Detection Method  
4.2. Materials and Methods 
4.2.1. Materials  
The materials used in this experiment were purchased from the following, the gold (III) 
chloride trihydrate (HAuCl4), sodium chloride, and sodium citrate were all purchased from 
Sigma Aldrich. The carcinoembryonic antigen protein used was purchased from Fitzgerald.  
While the aptamer used in this experiment was purchased from integrated DNA technologies, 
with the following sequence: 5’ – GGA ATC GGT GGC TTC ATG CTA GTC GCG GGC – 3’ 
All measurements were taken with Nanodrop 2000/2000c Spectrophotometers and 
evaluated at the two wavelengths of 520 nm and 650 nm in which the values were ratio.  
4.2.2. Preparation of Gold Nanoparticles  
The preparation of the AuNPs were made as a previously reported57. Briefly, a clean 
round-bottom flask was incubated with 3HCl:1HNO3 for at least one hour and rinsed with plenty 
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of distilled water. In 250 mL of double distilled water, the 50 L of 50% HAuCl4 was boiled 
with continuous stirring. When the solution was brought to a boil, 4.5 mL of 4.91 *10-2 M of 
sodium citrate was added to the solution. Then the solution was heated until the color turned to 
red and was heated for an extra ten minutes. The solution was then cooled to room temperature 
and then the concentration taken through absorption measurements using Beer Lambert’s law 
with the molar absorptivity () of 2.43 *108 L * mol-1 * cm-1 and evaluating the absorbance at 
520 nm with a 1 cm cuvette.  
4.2.3. Detection of Carcinoembryonic Antigen   
The detection of CEA was performed by following a previous experiment with some 
small changes100. Briefly, 20 L of 8M CEA aptamer 1 was diluted in binding buffer (500 mM 
NaCl, 2 mM MgCl2, 5 mM KCl, and 1 mM CaCl2) with 360 L of 5 nM AuNPs. This was 
incubated at room temperature with gentle mix for forty-five minutes. Then 20 L of various 
concentrations of CEA protein was incubated with the AuNP-aptamer1 solution, for thirty 
minutes with gentle mix at room temperature. To induce the color change, 25 L of 1 M NaCl 
was added as indicated in the scheme below.  
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Scheme 3. Representation of the Colorimetric Detection of CEA with Unmodified Gold 
Nanoparticles and CEA Aptamer 1  
The samples were then measured at 520 nm and 650 nm and ratio because when more 
aggregation present in the solution the higher the signal should be increased at 650 nm and 
decreased at 520 nm. The data was then plotted in Microsoft excel and given the graphs in the 
following section.  
4.3. Results  
To obtain the best results, many conditions needed to be optimized such as: buffer, 
AuNPs concentration, aptamer-1 concentration, sodium chloride concentration, the aptamer-
AuNPs absorption time and the time it takes the aptamer-1 binding to CEA. After the optimal 
conditions were set a calibration curve was determined along with its limit of detection, dynamic 
range, and reproducibility of the experiment evaluated as shown in the figures below.  These 
conditions were optimized sequentially while keeping all conditions constant except the 
condition being evaluated.    
  
48 
 
Figure 15. Optimization of Buffer Types 
 
Figure 16. Optimization of Starting Gold Nanoparticle Concentration  
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Figure 17. Starting Aptamer Concentration Optimization   
 
 Figures 18. Sodium Chloride Concentration Optimization  
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Figure 19. DNA Absorption Time Optimization  
 
Figure 20. Protein to DNA Binding Time Optimization  
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Once the optimal conditions were defined, the reproducibility, selectivity and the 
calibration curve was then accomplished.  
 
 
Figure 21. Reproducibility for Colorimetric Test 
From the data provided the standard deviation was calculated with the following 
equation:  
Standard Deviation Equation: 
𝑠 =  √
(𝑥 − 𝑥)̅̅ ̅2
𝑛 − 1
 
Sample Calculation of Standard Deviation using 150 ng/mL CEA data:  
𝑆 = √
(0.1091 − 0.1120)2 + (0.1076 − 0.1120)2 + (0.1076 − 0.1120)2 + (0.1887 − 0.1120)2 + (0.112 − 0.112)2
5 − 1
= 0.0054 
Once the standard deviation was calculated the relative standard deviation was calculated 
with the following equation:  
Relative Standard Deviation Equation:  
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Sample Calculation of Relative Standard Deviation using 150 ng/mL CEA data:  
𝑅𝑆𝐷 = (
0.0054
0.1120
) ∗  100 = 4.82 
These calculations were done with both the 150 ng/mL CEA sample and the blank as 
shown in which the is shown in the table below.  
Table 6. Reproducibility of CEA Detection 
 
 Blank  150 ng/mL CEA  
Average 0.083 0.112 
Standard 
Deviation  
0.0051 0.0053 
RSD (%) 6.18 4.82 
 
To ensure that this test is not only reproducible but also that this aptamer is only detecting 
the CEA protein a selectivity test was also accomplished using carbohydrate antigen 19-9 
(CA19-9) at 500 U/mL where the healthy cut-off value of 37 U/mL. With other proteins of 
bovine serum albumin (BSA) and human immunoglobulin G (IgG) at 50 nM of each protein.  
 
Figure 22. Selectivity for CEA Colorimetric Test 
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Figure 23. Depiction of Color change in Colorimetric Test  
In figure 24 the following concentrations were tested from left to right: Blank, 50 ng/mL, 
100 ng/mL, 200 ng/mL  and 400 ng/mL CEA.  
 
Figure 24. Calibration Curve for Aptamer One in Gold Colorimetric Test  
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From the calibration curve the linear regression was fitted with a line y=0.004x +0.0609 
in which allowed for the calculation of limit of detection in the following manner:  
Limit of Detection Calculation:  
𝐿𝑂𝐷 =
3 ∗ 𝑠𝑏𝑙
𝑚
 
Sample Calculation 
𝐿𝑂𝐷 =
3 ∗ 0.0071
0.003906
= 54.31 𝑛𝑔/𝑚𝐿 
4.4. Discussion  
In this experiment, a new aptamer was implemented for the detection of 
carcinoembryonic antigen protein with the use of unmodified gold nanoparticles for a simple 
colorimetric test. In order to get the best results, many parameters needed to be optimized. The 
parameters were optimized sequentially and were chosen based on the difference between the 
blank and actual signal. The first condition that was optimized was the type of buffer. The 
buffers that were tested were PBS, PBS(T), SSC, 20 mM Tris HCl and finally a binding buffer 
with the components of 500 mM NaCl, 2 mM MgCl2, 5 mM KCl, and 1 mM CaCl2. As clearly 
shown in figure 15, binding buffer had the best response, while the other buffers such as PBS, 
PBS(T) and SSC did not provide the proper environment to induce a color change when protein 
was present while tris HCl provided to high of background. Then the starting concentration of 
gold nanoparticles were tested starting form 1 nM to 7 nM in which 5 nM had the best response. 
The amount of aptamer concentration was also optimized by testing the following concentrations 
5, 8, 10, 12, 15, 20 M. Figure 16 clearly indicates that 8 M had the best response. Even though 
10  M had a similar response, the 8  M had a lower noise ratio which is why it was chosen. 
The amount of salt added to the solution is vitally important since it is what will induce the color 
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change. Therefor the concentrations of 0.5, 1, 2, 3, and 4 M were tested. At higher than 2 M the 
noise from the blank became exceptionally high, however zooming in on the samples 0.5, 1 and 
2 M in figure 18, indicated that 1 M was the best concentration of salt to use. Incubation times 
were also very important, and thus the amount of time for the aptamer to absorb onto the gold 
surface was tested starting with 0 to 60 minutes for fifteen minute intervals. As shown in figure 
19, 45 minutes was the optimal time, even though after 15 minutes the noise from the blank was 
greatly decreased but the greatest difference was shown in the 45 minutes therefor 45 minutes 
was the optimal time for the DNA absorption time onto the gold surface. Finally, the time it took 
for the interaction between DNA and protein to bind was also optimized where figure 20 clearly 
depicts that 30 minutes was the optimal time. After all the parameters were optimized lead to the 
experiment with the following conditions: each test should be accomplished in binding buffer 
with starting with 360 L 5 nM of AuNPs with 20 L of 8 M and incubating for 45 minutes at 
room temperature. Then 20 L of various amounts of concentration of protein was added and 
incubated for a further 30 minutes at room temperature. In the final step there was 25 L of 1 M 
NaCl. The color change could then be visualized and quantified using Nanodrop 2000/2000c 
Spectrophotometers.  
The color change was induced when the 1 M NaCl solution was added because salt can 
shield the negative charge on the gold nanoparticles allowing the particles to become closer 
together and aggregate. Upon aggregation, the size and shape of the gold nanoparticles change 
thus changing the color of the solution. Without the addition of salt the repulsion forces between 
the particles are too strong for the gold to aggregate102. When no protein of CEA is present, the 
aptamer could stabilize the AuNPs thus keeping the red color however when the CEA was 
present the aptamer having a higher binding affinity toward the protein would stop interacting 
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with the AuNPs and bind with the protein thus allowing for the distance between the AuNPs to 
shorten, causing aggregation and thus leading to a change of color from a red to purple. This 
change in color is gradual depending on the concentration of CEA present as demonstrated in 
figure 23.  
 Once the conditions were optimized the question of if this test is reproducibly became 
apparent. This was done by repeating the test five different times in triplicate form under the 
optimal conditions previously described. Then the relative standard deviation was calculated 
giving the test of less than 10% indicating that this test is indeed reproducible and stable. This 
method should give then same results multiple times.   
 Once the method proved to be reproducible the calibration curve was then determined as 
shown in figure 24. This test provided to have a limit of detection of visually with 50 ng/mL of 
CEA as shown in figure 23, however by measuring the absorption ratio of 650/520 and plotting a 
linear trend was observed from 0 to 400 ng/mL of CEA. By fitting the curve the limit of 
detection was calculated to be 54.31 ng/mL of CEA by taking the average of blank plus three 
times the standard deviation. With a healthy cut-off value of CEA in regular patients to be 5 
ng/mL this method has proven to not be very sensitive. However, this shows promise that the 
aptamer can be implemented in other techniques. There are other analytical methods in which 
aptamers can be implemented in such as fluorescence, chemiluminescence, or even 
electrochemical.  
Since the test has proven to be reproducible, another question that is typically asked is, is 
this aptamer selective and can it definitively detect CEA when no other protein are present. Since 
multiple negative selection rounds were performed in the graphene oxide SELEX, this aptamer 
should be selective however, it is should be verified. The proteins carbohydrate antigen 19-9 (CA 
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19-9), bovine serum albium (BSA) and human IgG were tested. Figure 22 indicates that there are 
no large response to other proteins even when there were large concentrations of other protein 
present. This indicates that the aptamer is selective toward CEA. 
4.5. Conclusion  
In conclusion, this method has proven successful in implementing the newly designed 
aptamer specific toward CEA for an easy detection of CEA with a linear range from 50 ng/mL to 
400 ng/mL of CEA and a calculated limit of detection of 54.3 ng/mL CEA and a visual detection 
of 50 ng/mL. This is the first test in which this aptamer has been implemented and shows much 
promise for future analytical and potentially point-of-care testing of CEA. Another potential 
future possibility is to combine the aptamer used in this study with another aptamer that has been 
reported to implement in a sandwich sort of assay. Either way the future applications for this 
aptamer are endless.   
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CHAPTER 5. CONCLUSION 
This thesis was broken down into three sections, the first was to identify an aptamer 
specific towards carcinoembryonic antigen (CEA) using graphene oxide assisted SELEX. In that 
portion of the experiment an aptamer was identified based on frequency of number of sequences 
found by NexGen Sequencing. Aptamer one was the aptamer had the highest number of 
appearances and was thus used for future experiments.  
The second part of this experiment was to calculate the dissociation constant for the 
aptamer that had been previously identified using surface plasmon resonance (SPR) and to 
compare that value with an aptamer that had already been identified with a different SELX 
method. This was done for two reasons, the first was quantify the quality of the aptamer 
identified and the second was to directly compare aptamer one to the reported aptamer. The 
dissociation constant for the reported aptamer was found to be 828.26  23.99 nM while the 
aptamer isolated with the graphene oxide assisted SELEX was found to be 253.68 15.75 nM. 
This indicates that the aptamer isolated from the GO-SELEX binds more tightly to CEA than the 
aptamer isolated from the affinity-SELEX, thus graphene oxide can sufficiently separate the 
specific from the non-specific strands indicating that this GO-SELEX could be used for future 
experiments.  
 In the final part of this experiment was to successfully implement aptamer one for the 
detection of CEA using unmodified gold nanoparticles. This method was proven to successfully 
detect CEA by evaluating a simple color change. This method provided a linear range from 50 
ng/mL to 400 ng/mL of CEA and a calculated limit of detection of 54.3 ng/mL CEA and a visual 
detection of 50 ng/mL. This is the first test in which this aptamer has been implemented and 
shows much promise for future analytical and potentially point-of-care testing of CEA.  
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This experiment was successful for a starting off point for many future experiments, such as 
performing the graphene-oxide assisted SELEX for other proteins such as carbohydrate antigen 
19-9 (CA 19-9), complementary factor B (CFB), and C4BP𝛂, which are common biomarkers for 
pancreatic cancer. There are also a lot of potential for the use of the aptamer that has been 
identified, since the limit of detection was so poor, it would be easy to implement this aptamer in 
other analytical techniques such as fluorescence, chemiluminescent and electrochemical. 
Another potential future possibility is to combine the aptamer one used with a reported aptamer 
to implement in a sandwich assay for point of care diagnositcs. Either way the future applications 
for this aptamer are endless.   
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